Cytochrome P450 CYP1B1 (190-198) [Homo sapiens]
(Synonyms: H2N-Phe-Leu-Asp-Pro-Arg-Pro-Leu-Thr-Val-OH ) 目录号 : GP10141
Sequence: H2N-FLDPRPLTV-OH
![Cytochrome P450 CYP1B1 (190-198) [Homo sapiens] Chemical Structure](/media/struct/GP1/GP10141.png "Cytochrome P450 CYP1B1 (190-198) [Homo sapiens] Chemical Structure")
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
H2N-FLDPRPLTV-OH
Cytochrome P450 CYP1B1 is a dioxin-inducible form of the cytochrome P450 family of xenobiotic metabolizing enzymes1.
HLA-A2 restricted, CYP1B1 190–198 (CYP190) peptide specific T cell responses are induced in HLA-A2Kb transgenic mice by immunization with ZYC300, a PLG microparticle formulation that contains a plasmid DNA encoding the tumor associated antigen CYP1B12, 3.
Each successive co-application of EPT contributes to an escalating T cell response that can be observed 2 weeks after the last immunization, and that even a single EPT when given with the usually ineffective 30 µg dose of ZYC300 was able to induce a detectable CD8+ CYP190 specific T cell response4.
References:
1. Murray,G.I., Taylor, M. C., et al 1997; Tumor-specific Expression of Cytochrome P450 CYP1B11. Cancer Research. 57:3026-3031.
2. Luby TM, Cole GA, Baker L, Kornher JS, Ramstedt U, Hedley ML. Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor associated antigen cytochrome P450 1B1. Clinical Immunology 2004;112(1):45–53.
3. Maecker DH, Sherr RH, Vonderheide MS, von Bergwelt-Baildon MS, Hirano N, Anderson K, et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 2003;102(9):3287–94.
4. Barbon, C. M., Baker, L et al 2010 In vivo electroporation enhances the potency of poly-lactide co-glycolide (PLG) plasmid DNA immunization. Vaccine; 28:7852-7864
| Cas No. | SDF | ||
| 别名 | H2N-Phe-Leu-Asp-Pro-Arg-Pro-Leu-Thr-Val-OH | ||
| Canonical SMILES | NC(C(NC(CC(C)C)C(NC(CC(O)=O)C(N1C(C(NC(CCCNC(N)=N)C(N2CCCC2C(NC(CC(C)C)C(NC(C(C)O)C(NC(C(C)C)C(O)=O)=O)=O)=O)=O)=O)CCC1)=O)=O)=O)CC3=CC=CC=C3 | ||
| 分子式 | C50H80N12O13 | 分子量 | 1057.24 |
| 溶解度 | ≥ 105.7mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.9459 mL | 4.7293 mL | 9.4586 mL |
| 5 mM | 0.1892 mL | 0.9459 mL | 1.8917 mL |
| 10 mM | 0.0946 mL | 0.4729 mL | 0.9459 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。